Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
23:13
The Hungarian government will offer owners of eligible diesel cars 5,000 forints per month until the end of the year
22:57
Peter Magyar announces changes to Hungary’s adoption law for same-sex couples
22:38
Bucharest entered the Book of Records with “The Table That Unites.” Ciucu: “There was a big dining room today, in Constitution Square”
22:14
Anthropic’s CEO calls for slowing AI development, warning that intelligent agents could take control of the internet in the coming months
21:26
Sergey Lavrov responds to Volodymyr Zelensky: “Let him come to Moscow” for a meeting with Vladimir Putin
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
